5 completed. 3 Phase 1, 1 Phase 2, 1 Phase 3.
By phase and status
Follow NNC0195-0092: new trials by email Literature Review of NNC0195-0092 trials Research Report on NNC0195-0092
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency somapacitan, Norditropin® FlexPro® pen - Growth Hormone Disorder, Growth Hormone Deficiency in Children Phase 2 Completed Novo Nordisk A/S 76 2016-03-31 2026-01-16 Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency. somapacitan, somatropin, placebo - Growth Hormone Disorder, Adult Growth Hormone Deficiency Phase 3 Completed Novo Nordisk A/S 301 2014-10-31 2020-11-23 A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency somapacitan, somatropin - Growth Hormone Disorder, Growth Hormone Deficiency in Children Phase 1 Completed Novo Nordisk A/S 32 2013-12-16 2020-12-24 A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency somapacitan, Norditropin NordiFlex® - Growth Hormone Disorder, Adult Growth Hormone Deficiency Phase 1 Completed Novo Nordisk A/S 35 2012-10-12 2020-12-24 First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects somapacitan, placebo (somapacitan) - Growth Hormone Disorder, Adult Growth Hormone Deficiency Phase 1 Completed Novo Nordisk A/S 105 2012-01-16 2020-12-24
Conditions studied Dwarfism, Pituitary (3)
Sponsors Novo Nordisk A/S (5)
Countries Sweden (4) · Germany (3) · Israel (3) · Austria (2) · Belgium (2) · Brazil (2) · France (2) · India (2) · Japan (2) · Norway (2) · Slovenia (2) · Turkey (Türkiye) (2) · Ukraine (2) · United States (2) · Australia (1)
Results publications PMID 29671202 , PMID 33864240 , PMID 25013997 , PMID 26727076 , PMID 28656605 , PMID 31917835 , PMID 32022863 , PMID 34964458 , PMID 36380045 , PMID 36995872 , PMID 39991735 , PMID 42369274
NIH funding 2015 (1)